SGLT2 Inhibitors Are Associated With Reduced Cardiovascular Disease in Patients With Type 2 Diabetes: An Analysis of Real-World Data

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Objective: To assess the association between sodium-glucose cotransporter-2 (SGLT2) inhibitors and other second-line diabetes therapies with risk of cardiovascular disease (CVD), as well as conduct head-to-head comparisons between SGLT2 inhibitors. Patients and Methods: Using data from the MarketScan databases (January 1, 2013, through December 31, 2019), SGLT2 inhibitor users were matched with up to five other second-line therapy users by age, sex, date of enrollment, and date of second-line therapy initiation. The primary composite outcome included stroke, atrial fibrillation, myocardial infarction, and heart failure. Hazard ratios were estimated, adjusting for demographics and a propensity score reflecting comorbidities and medications. Results: In this study population of 313,396 patients (mean age 53±10 years; 47% female), 9787 incident CVD events occurred over a median follow-up of 1.36 years. After multivariable adjustments, SGLT2 inhibitor users had a lower risk of CVD than other second-line therapy users (HR, 0.66; 95% CI, 0.62 to 0.71). Significant associations were also observed when each CVD outcome was assessed separately. No differences were noted when comparing individual SGLT2 inhibitors. Conclusion: SGLT2 inhibitors were associated with a clinically meaningfully lower CVD risk in the real-world setting. In head-to-head comparisons, the different SGLT2 inhibitors were consistent in their protective associations with CVD. This suggests that as a class, SGLT2 inhibitors may have widespread benefit in preventing CVD among patients with type 2 diabetes.

Original languageEnglish (US)
Pages (from-to)985-996
Number of pages12
JournalMayo Clinic Proceedings
Volume98
Issue number7
DOIs
StatePublished - Jul 2023

Bibliographical note

Funding Information:
Grant Support: This work was supported by grants from the National Heart Lung and Blood Institute (K24HL159246 [PLL], R01HL131579 [PLL], K24HL155813 [LYC], and K24HL148521 [AA]).

Publisher Copyright:
© 2023 Mayo Foundation for Medical Education and Research

PubMed: MeSH publication types

  • Journal Article

Fingerprint

Dive into the research topics of 'SGLT2 Inhibitors Are Associated With Reduced Cardiovascular Disease in Patients With Type 2 Diabetes: An Analysis of Real-World Data'. Together they form a unique fingerprint.

Cite this